Feature

Nature Biotechnology 26, 509 - 517 (2008)
Corrected online: 8 July 2008 | doi:10.1038/nbt0508-509



There is an Erratum (July 2008) associated with this Feature.

Is personalized medicine finally arriving?

Malorye Allison1

It's no gold rush, but dozens of players are emerging in personalized medicine, with biotechs, big and small, leading the way. Some big pharma companies and even payers remain skeptical, but economics aside, the real winners will be patients.

Top
  1. Malorye Allison is a freelance writer based in Acton, Massachusetts.
* In the version of this article initially published, Table 1 (page 510-511) contained two errors. In the entry for Agendia, the product Mammaprint was described as providing information on chemotherapy options for breast cancer patients. In fact Mammaprint is a prognostic test. In the entry for Genomic Health, the product Oncotype Dx was described as providing information on breast cancer recurrence. Oncotype DX also provides information on the response to chemotherapy.

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.

NEWS AND VIEWS

Chutes and Ladders on the Critical Path:Comparative Effectiveness, Product Value, and the Use of Biomarkers in Drug Development

Clinical Pharmacology & Therapeutics News and Views

Extra navigation

Search PubMed for

Open Innovation Challenges

naturejobs

More science jobs
Post a job for free

ADVERTISEMENT